Biosimilars

Discover the landscape of Biosimilars in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and intelligence on Biosimilars, helping you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Jiangsu Nhwa Signs Exclusive Global Licensing Deal with Somnivera – Clinical‑Stage Sleep‑Disorder Asset Backed by Up to US$517.5 Million in Potential Value
CompanyDeals

Jiangsu Nhwa Signs Exclusive Global Licensing Deal with Somnivera – Clinical‑Stage Sleep‑Disorder Asset Backed by Up to US$517.5 Million in Potential Value

Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) announced an exclusive licensing agreement with Somnivera, Inc., a U.S. biotechnology company, for an investigational clinical‑stage drug candidate targeting sleep disorders. Under the…

MindRank Signs Exclusive Greater China Commercialization Deal With Sunshine Mandi for MDR‑001 – AI‑Designed Oral GLP‑1 Candidate in Phase III for Obesity, Worth Up to RMB 1.75 Billion

MindRank Signs Exclusive Greater China Commercialization Deal With Sunshine Mandi for MDR‑001 – AI‑Designed Oral GLP‑1 Candidate in Phase III for Obesity, Worth Up to RMB 1.75 Billion

NMPA Approves Lilly's Jaypirca (Pirtobrutinib) as First‑Line Monotherapy for CLL/SLL – Non‑Covalent BTK Inhibitor Completes Line‑of‑Therapy Progression in China

NMPA Approves Lilly’s Jaypirca (Pirtobrutinib) as First‑Line Monotherapy for CLL/SLL – Non‑Covalent BTK Inhibitor Completes Line‑of‑Therapy Progression in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Sinocelltech Group Receives NMPA Approval for Bevacizumab Biosimilar for Multiple Cancers

CompanyDeals

Biomm Secures Late-Stage Biosimilar Candidate BAT2206 from Bio-Thera Solutions

CompanyDrug

CSPC Pharmaceutical’s Biosimilar Omalizumab Accepted for Review by China’s NMPA

CompanyDrug

Henlius Biotech’s HLX13 Biosimilar Gets NMPA Approval for Liver Cancer Clinical Trial

CompanyDeals

Mega Lifesciences Secures Exclusive Rights for Bio-Thera’s Bevacizumab Biosimilar in Indonesia

CompanyDrug

Sinocelltech Group Launches Biosimilar Version of AbbVie’s Humira in China

CompanyDrug

Sinocelltech Group Receives NMPA Approval for Biosimilar Version of Humira

CompanyDrug

Chia Tai Tianqing’s Biosimilar Rituximab Approved by China’s NMPA for Lymphoma Treatments

Show More